Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Enterprise Value: 2018-2025

Historic Enterprise Value for Neurogene (NGNE) over the last 6 years, with Sep 2025 value amounting to -$18.1 million.

  • Neurogene's Enterprise Value fell 104.45% to -$18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$897.6 million, marking a year-over-year decrease of 684.78%. This contributed to the annual value of $27.2 million for FY2024, which is 117.92% up from last year.
  • Latest data reveals that Neurogene reported Enterprise Value of -$18.1 million as of Q3 2025, which was up 70.51% from -$61.3 million recorded in Q2 2025.
  • Neurogene's Enterprise Value's 5-year high stood at $484.7 million during Q1 2024, with a 5-year trough of -$151.6 million in Q4 2023.
  • Over the past 3 years, Neurogene's median Enterprise Value value was -$43.7 million (recorded in 2023), while the average stood at $67.6 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 1,028.92% in 2024, then slumped by 124.30% in 2025.
  • Quarterly analysis of 3 years shows Neurogene's Enterprise Value stood at -$151.6 million in 2023, then surged by 117.92% to $27.2 million in 2024, then tumbled by 104.45% to -$18.1 million in 2025.
  • Its Enterprise Value was -$18.1 million in Q3 2025, compared to -$61.3 million in Q2 2025 and -$117.8 million in Q1 2025.